Catch the latest news reports on The Big Story, The Straits Times’ weekday online news programme. 

Patients with Alzheimer’s disease - the most common cause of dementia - may soon get a new drug that can slow progression of the disease, a recent study has found.

The Phase 3 trial of the antibody drug known as lecanemab involved nearly 1,800 participants, including 13 patients from Singapore’s National University Hospital (NUH).

Associate Professor Christopher Chen, visiting consultant in the Department of Psychological Medicine at NUH, joins the programme to discuss this development. Pro Chen is part of the team conducting the trial.

Separately, those aged 12 and above in Singapore can get the bivalent Pfizer-BioNTech/Comirnaty Covid-19 vaccine from Dec 12 to enhance their protection against the Omicron variants of the coronavirus.